文献速递新发突发、热带与寄生虫病

双氢青蒿素-哌喹与氯喹治疗巴西间日疟的随机试验

Dihydroartemisinin-piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial.
PubMed 文献 · Lancet Infect Dis · 2026-05-11

Curavivax 是一项在巴西马瑙斯开展的开放标签、单中心、随机试验,纳入 419 例间日疟患者,比较双氢青蒿素-哌喹与氯喹联用伯氨喹(第 0 天或延迟至第 42 天)的疗效。结果显示,双氢青蒿素-哌喹联合伯氨喹第 42 天复发率与氯喹联合伯氨喹相似,而单用双氢青蒿素-哌喹(延迟伯氨喹)复发率显著低于单用氯喹(延迟伯氨喹)。所有治疗方案耐受性良好。

要点

  • 双氢青蒿素-哌喹联合伯氨喹第 42 天复发率与氯喹联合伯氨喹相似。
  • 单用双氢青蒿素-哌喹(延迟伯氨喹)复发率显著低于单用氯喹(延迟伯氨喹)。
  • 所有治疗方案耐受性良好。

核心结论

  • 双氢青蒿素-哌喹联合伯氨喹(第 0 天或延迟至第 42 天)的高疗效和早期复发预防支持其在拉丁美洲用于间日疟治疗。

研究设计与样本

  • Curavivax 为开放标签、单中心、平行组、随机试验,在巴西马瑙斯公共传染病参考中心进行。
  • 纳入 419 例患者,随机分配(1:1:1:1)至氯喹联合伯氨喹(n=114)、双氢青蒿素-哌喹联合伯氨喹(n=112)、氯喹联合延迟伯氨喹(n=98)、双氢青蒿素-哌喹联合延迟伯氨喹(n=95)。
  • 患者年龄大于 6 个月,镜检确诊间日疟,体重不超过 100 kg,葡萄糖-6-磷酸脱氢酶活性大于正常值的 30%。
  • 主要结局为符合方案人群第 42 天复发率;安全性在所有至少接受一剂研究药物的参与者中评估。

主要发现

  • 所有治疗方案耐受性良好。

临床怎么用

  • 在拉丁美洲间日疟治疗中,可考虑使用双氢青蒿素-哌喹作为氯喹的替代裂殖体杀灭剂,联合伯氨喹(第 0 天或延迟至第 42 天)以预防早期复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to evaluate the efficacy and tolerability of dihydroartemisinin-piperaquine as an alternative schizontocide to chloroquine for the treatment of Plasmodium vivax malaria in Brazil, where early recurrences despite chloroquine therapy and operational challenges with primaquine adherence highlight the need to assess alternative treatment regimens. METHODS: Curavivax was an open-label, single-centre, parallel-group, randomised trial done in a public reference centre for infectious diseases in Manaus (Brazilian Amazon). Patients older than 6 months with microscopically confirmed P vivax malaria, weighing up to 100 kg, with glucose-6-phosphate dehydrogenase activity greater than 30% of normal, were randomly assigned (1:1:1:1), based on a computer-generated list of blocks of five participants, to dihydroartemisinin-piperaquine or chloroquine plus primaquine initiated on day 0 or delayed until day 42. Dihydroartemisinin-piperaquine (40/320 mg or 20/160 mg oral tablets) and chloroquine (150 mg oral tablets) were administered once daily for 3 days. Primaquine (15 mg oral tablets) was administered once daily for 14 days. All medicines were dosed by bodyweight and dispensed open-label. The primary outcome was the recurrence rate at day 42 in the per-protocol population. Safety was assessed in all participants who received at least one dose of study medication. This trial was registered with ClinicalTrials.gov, NCT03208907, and is completed. FINDINGS: Between July 5, 2018, and Jan 13, 2021, 1649 patients were screened for eligibility, 419 of whom were randomly assigned to chloroquine plus primaquine (n=114), dihydroartemisinin-piperaquine plus primaquine (n=112), chloroquine plus delayed primaquine (n=98), and dihydroartemisinin-piperaquine plus delayed primaquine (n=95). One patient in the chloroquine plus primaquine group was excluded owing to a severe protocol deviation. 287 (69%) of 418 patients were male and 131 (31%) were female. Day 42 recurrence rate in the per-protocol population was similar for chloroquine plus primaquine (2·0% [95% CI 0·2-7·0]) and dihydroartemisinin-piperaquine plus primaquine (1·0% [0·0-5·3]; hazard ratio [HR] 0·48 [95% CI 0·00-40 209·06; p=0·44); whereas dihydroartemisinin-piperaquine alone (delayed primaquine; 2·4% [0·3-8·5]) was superiorto chloroquine alone (delayed primaquine; 27·3% [18·3-37·8]; HR 0·08 [95% CI 0·00-0·22]; p<0·0001). All treatments were well tolerated. INTERPRETATION: The high therapeutic efficacy and early recurrence prevention with dihydroartemisinin-piperaquine with primaquine started on day 0 or delayed to day 42 supports the use of this schizontocide for P vivax treatment in Latin America. FUNDING: Ministry of Health of Brazil and the National Council for Scientific and Technological Development.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Baía-da-Silva DC, Machado KVA, Rabelo ALR, et al. Dihydroartemisinin-piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial. Lancet Infect Dis. 2026. PMID: 42114535. doi:10.1016/S1473-3099(26)00139-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。